PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics…
FRAMINGHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global advisory firm and CRO, today announced the appointment…
FRAMINGHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global advisory firm and CRO, today announced the appointment…
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s…
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s…
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated…
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated…
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all…